Oryzon Genomics - More to come after a year of data readouts
As we expected, 2019 was a year of data readouts for epigenetics specialist Oryzon. The company presented new data from the ongoing Phase IIa...
787 Views
Oryzon Genomics - Maturing ALICE trial dataset continues to impress
On 9 December 2019, Oryzon presented more data from the Phase II ALICE trial at the 61st ASH annual meeting in Orlando, Florida. The single-arm,...
1.7k Views
Oryzon Genomics - Interim Phase II CLEPSIDRA results at ESMO
On 28 September 2019, Oryzon presented additional data from its Phase IIa CLEPSIDRA trial with iadademstat, a selective LSD1 inhibitor, at the ESMO...
847 Views
Oryzon Genomics - Phase IIa trial in Alzheimer’s disease initiated
According to the latest news from Oryzon, the first Alzheimer’s disease (AD) patients (3/90) were recruited into the Phase IIa ETHERAL clinical...
60 Views
Oryzon Genomics - Multiple data readouts in 2019 within cash reach
Oryzon is ramping up its R&D programme and plans to conduct a total of four mid-stage clinical trials with lead assets ORY-1001 (a specific...
94 Views